WithdrawnPhase 2

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection

Stopped: New coordinating center has been defined (Massachusetts General Hospital)

0Started 2020-03-01

Plain-language summary

The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Laboratory confirmed COVID19 infection defined with a positive RT-PCR from any specimen.
✓. Hospital admission with at least one of the following:
✓. Spontaneous breathing with or without hypoxia of any degree. Gas exchange and ventilation maybe assisted by any continuous continuous airway pressure (CPAP), or any system of Non Invasive Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP) ≤ 10 cmH2O.
✓. ≤ 8 days since onset of the symptoms

Exclusion criteria

✕. Pregnancy, or positive pregnancy test in a predose examination
✕. Open tracheostomy
✕. Therapy with high flow nasal cannula
✕. Clinical controindication, as deemed by the attending physician

What they're measuring

Reduction in the incidence of intubation and mechanical ventilation

Timeframe: 28 days

Trial details

NCT IDNCT04290858

SponsorXijing Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-03-01

View on ClinicalTrials.gov More Coronavirus Infections trials